Free Trial

Amarin (AMRN) News Today

$0.78
-0.01 (-1.26%)
(As of 07/19/2024 ET)
Amarin logo with Medical background
Amarin (NASDAQ:AMRN) Rating Lowered to Hold at StockNews.com
StockNews.com downgraded shares of Amarin from a "buy" rating to a "hold" rating in a research note on Thursday.
Amarin logo with Medical background
Q3 2025 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Reduced by Analyst
Amarin Co. plc (NASDAQ:AMRN - Free Report) - Investment analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Amarin in a research note issued on Wednesday, June 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings
Amarin logo with Medical background
Amarin Co. plc (NASDAQ:AMRN) Sees Significant Growth in Short Interest
Amarin Co. plc (NASDAQ:AMRN - Get Free Report) was the recipient of a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 19,020,000 shares, a growth of 20.3% from the May 31st total of 15,810,000 shares. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is currently 12.8 days.
Amarin logo with Medical background
Amarin (NASDAQ:AMRN) Downgraded by StockNews.com to Hold
StockNews.com downgraded Amarin from a "buy" rating to a "hold" rating in a research note on Tuesday.
Amarin logo with Medical background
Amarin (NASDAQ:AMRN) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reissued an "overweight" rating on shares of Amarin in a research report on Tuesday.
Amarin (NASDAQ:AMRN) Raised to Buy at StockNews.com
StockNews.com upgraded shares of Amarin from a "hold" rating to a "buy" rating in a research report on Monday.
Amarin Board of Directors Announces CEO Transition
Zacks Research Weighs in on Amarin Co. plc's FY2024 Earnings (NASDAQ:AMRN)
Amarin Co. plc (NASDAQ:AMRN - Free Report) - Zacks Research lifted their FY2024 earnings estimates for Amarin in a research report issued on Wednesday, May 22nd. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of ($0.16) per share for the
Q2 2025 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Reduced by Zacks Research
Amarin Co. plc (NASDAQ:AMRN - Free Report) - Research analysts at Zacks Research lowered their Q2 2025 EPS estimates for shares of Amarin in a research report issued to clients and investors on Tuesday, April 30th. Zacks Research analyst R. Department now expects that the biopharmaceutical compan
Amarin (NASDAQ:AMRN) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Amarin (NASDAQ:AMRN - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $56.52 million during the quarter, compared to analyst estimates of $51.34 million. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. During the same period in the previous year, the company posted ($0.04) EPS.
Here's what Wall Street expects from Amarin's earnings report
Amarin Q1 2024 Earnings Preview
Amarin Co. plc (NASDAQ:AMRN) Short Interest Update
Amarin Co. plc (NASDAQ:AMRN - Get Free Report) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 15,840,000 shares, a drop of 12.1% from the March 31st total of 18,020,000 shares. Based on an average daily trading volume, of 1,680,000 shares, the days-to-cover ratio is presently 9.4 days.
AMRN Apr 2024 3.000 call
AMRN Apr 2024 1.500 put
AMRN May 2024 1.000 call
FY2024 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Boosted by Analyst
Amarin Co. plc (NASDAQ:AMRN - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for shares of Amarin in a research note issued to investors on Monday, March 4th. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will earn ($0
AMRN Mar 2024 0.500 call
Amarin Full Year 2023 Earnings: Beats Expectations
13D Management LLC Sells 2,579,723 Shares of Amarin Co. plc (NASDAQ:AMRN)
13D Management LLC lessened its stake in shares of Amarin Co. plc (NASDAQ:AMRN - Free Report) by 63.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,501,677 shares of the biopharmaceuti
Get Amarin News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

[URGENT] Altcoin Winning Picks (Ad)

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

AMRN Media Mentions By Week

AMRN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AMRN
News Sentiment

0.00

0.78

Average
Medical
News Sentiment

AMRN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AMRN Articles
This Week

2

2

AMRN Articles
Average Week

Get Amarin News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:AMRN) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners